一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Pharmacological research >>article
Pharmacological research

Pharmacological research

IF: 9.1
Download PDF

The potential of TAOK1 as a new therapeutic target for the treatment of cancer cachexia-associated muscle atrophy

Published:6 May 2025 DOI: 10.1016/j.phrs.2025.107763
Ruiqin Zhang , Nan Li , Ke Yu , Qiongsen Wang , Meng Fan , Xiongwen Zhang , Xuan Liu

Abstract

Cancer cachexia, a multifactorial metabolic syndrome impacts 50–80?% cancer patients, is mainly characterized by skeletal muscle atrophy. In this study, we demonstrated that the thousand-and-one amino acid kinase 1 (TAOK1) was activated in both C2C12 myotubes treated with simulated cancer cachexia injuries as well as in muscle tissues of mice inoculated with various types of tumor cells. Results of phosphoproteomic analysis also showed the increase in phosphorylation of TAOK1 in myotubes induced by simulated cancer cachexia injuries. Knockdown of TAOK1 in C2C12 myoblasts resulted in resistance to cancer cachexia-associated myotube atrophy. Comparing the protein expression profiles of C2C12-TAOK1-KO myotubes and that of control myotubes using proteomic analysis found that, TAOK1 knockout resulted in increased expression of muscle-related proteins and decreased expression of proteins related to MAPK pathway and ubiquitin-proteasome system (UPS). Results of Western blotting analysis confirmed the involvement of TAOK1/MAPK/FoxO3/UPS pathway in cancer cachexia-associated myotube atrophy, and suggested that TAOK1 knockout could ameliorate increased protein degradation but not decreased protein synthesis under cancer cachexia. CP43, a synthesized TAOK1 inhibitor, could ameliorate both in vitro myotube atrophy of C2C12 myotubes under simulated cancer cachexia injuries as well as in vivo muscle atrophy of cancer cachexia mice inoculating with C26 colon tumor cells. In conclusion, our study provides evidence that TAOK1 plays critical roles in activation of protein degradation under cancer cachexia thus targeting TAOK1 might be a potential therapy strategy for treatment of cancer cachexia-associated muscle atrophy.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
PD 98059 167869-21-8 C16H13NO3 287 suppliers $14.00-$71316.00
PD 98059 167869-21-8 C16H13NO3 287 suppliers $14.00-$71316.00
PD 98059 167869-21-8 C16H13NO3 287 suppliers $14.00-$71316.00
PD 98059 167869-21-8 C16H13NO3 287 suppliers $14.00-$71316.00

Similar articles

IF:5.4

The Cancer Chemopreventive and Therapeutic Potential of Tetrahydrocurcumin.

ACS Applied Energy Materials Ching-Shu Lai,?Chi-Tang Ho,etc Published: 29 May 2020
IF:4.2

Maslinic Acid: A New Compound for the Treatment of Multiple Organ Diseases.

Molecules Yan He,?Yi Wang,etc Published: 9 December 2022
IF:1.4

Sodium thiosulfate: new hope for the treatment of calciphylaxis.

Seminars in Dialysis Melvin R Hayden, David J A Goldsmith,etc Published: 1 May 2010
蛟河市| 漳州市| 怀集县| 营山县| 商洛市| 灵石县| 铜山县| 张家界市| 西乡县| 剑阁县| 阿勒泰市| 兰州市| 黄浦区| 安远县| 和平区| 屯留县| 南部县| 晋宁县| 浪卡子县| 赣榆县| 静宁县| 锦州市| 乌鲁木齐市| 宜兰县| 兴隆县| 城步| 抚顺县| 腾冲县| 九寨沟县| 日土县| 崇阳县| 新兴县| 青河县| 花垣县| 景谷| 泌阳县| 枞阳县| 宁武县| 邵阳市| 耿马| 山东省|